App-Quantinova.ai

Predictors of drug-free remission in rheumatoid arthritis: results from the prospective biomarkers of remission in rheumatoid arthritis(BIORRA study

K.F. Baker - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

Hydroxychloroquine

Predictors of fracture and low bone mineral density in patients with history of parental fracture

M. Dey - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Giant cell arteritis

Medroxyprogesterone

Probability and impact of achieving low disease activity or remission in patients with psoriatic arthritis treated with apremilast: pooled analysis of the palace 1–3 phase 3 trials

I. McInnes - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Psoriatic arthritis

Apremilast

Prophylactic and therapeutic activity of alkaline phosphatase in arthritic rats: single agent activity and in combination with methotrexate

D.M. Chandrupatla - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Inflammatory Arthritis

Alkaline phosphatase

Production and characterization of acellular human liver matrix: potential auxiliary liver graft

Hakeem A - International Conference on Tissue Engineering & Regenerative Medicine (ICTERM) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

DE-074

BK virus nephropathy in renal transplant recipient: A single centre experience

Ghulam Farid Rana - Global Nephrologists Annual Meeting , 2018

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

BK virus nephropathy

N/A

Long-term graft survival in underweight patients following renal transplantation: A single centre ten-year experience

Banan Abbas Mustafa Osman - Global Nephrologists Annual Meeting , 2018

Therapeutic Area

Disease

Drug/Treatment

Nephrology

End stage renal disease

N/A

The pathophysiology of essential hypertension in young/middle-age, and treatment implications

John Malcolm Cruickshank - Global Nephrologists Annual Meeting , 2017

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Essential arterial hypertension

N/A

Should all patients with posterior urethral valves be routinely circumcised?

Jonathan Goring* - Society for Paediatric Urology (SPU) , 2017

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Vesicoureteral reflux

N/A

Comparison of connective tissue content and contractility in exstrophy and posterior urethral valves

Kevin Cao - Society for Paediatric Urology (SPU) , 2019

Therapeutic Area

Disease

Drug/Treatment

Urology

Bladder dysfunction

N/A

Long-term outcomes in EV-301 24-month findings from the phase 3 trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma.

Jonathan E. Rosenberg - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2022

Therapeutic Area

Disease

Drug/Treatment

Urology

Advanced Urothelial Carcinoma

Enfortumab vedotin

The prognostic role of nephrectomy in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with immunotherapy according to the novel prognostic Meet-URO score Subanalysis of the Meet-URO 15 study.

Sara Elena Rebuzzi - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2022

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Metastatic Renal Cell Cancer

Nivolumab

Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (aUC) Long-term outcomes from JAVELIN Bladder 100 in subgroups defined by response to 1L chemotherapy.

Begoña Pérez-Valderrama - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2022

Therapeutic Area

Disease

Drug/Treatment

Urology

Advanced Urothelial Carcinoma

Carboplatin

Long-term outcomes in patients with advanced urothelial carcinoma (UC) who received avelumab first-line (1L) maintenance with or without second-line (2L) treatment Exploratory analyses from JAVELIN Bladder 100.

Joaquim Bellmunt - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2022

Therapeutic Area

Disease

Drug/Treatment

Urology

Advanced Urothelial Carcinoma

Carboplatin

Rafael Morales-Barrera - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2022

Therapeutic Area

Disease

Drug/Treatment

Urology

Advanced Urothelial Carcinoma

Pembrolizumab

Benchmarking maintenance therapy survival in first-line advanced urothelial carcinoma using disease modeling.

Matt D. Galsky - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2022

Therapeutic Area

Disease

Drug/Treatment

Urology

Advanced Urothelial Carcinoma

1L platinum

SAMETA An open-label, three-arm, multicenter, phase III study of savolitinib + durvalumab versus sunitinib and durvalumab monotherapy in patients with MET-driven, unresectable, locally advanced/metastatic papillary renal cell carcinoma (PRCC).

Toni K. Choueiri - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2022

Therapeutic Area

Disease

Drug/Treatment

Urology

Renal cell carcinoma

Savolitinib

Alkaline phosphatase (ALP) decline and overall survival (OS) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 (Ra-223) in the REASSURE study.

Nicholas D. James - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2022

Therapeutic Area

Disease

Drug/Treatment

Urology

Metastatic castration-resistant prostate cancer

Alkaline phosphatase

Activation of the AKT pathway and outcomes in patients (pts) treated with or without ipatasertib (ipat) in metastatic castration-resistant prostate cancer (mCRPC) Next-generation sequencing (NGS) data from the phase III IPATential150 trial.

Christopher Sweeney - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2022

Therapeutic Area

Disease

Drug/Treatment

Urology

Metastatic castration-resistant prostate cancer

Ipatasertib

Impact of activating androgen receptor (AR) mutations on AR sensitivity to alternative ligands and response to ODM-208, a selective, first-in-class CYP11A1 inhibitor, in patients with advanced metastatic castration-resistant prostate cancer (mCRPC).

Alice Bernard-Tessier - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2022

Therapeutic Area

Disease

Drug/Treatment

Urology

Metastatic castration-resistant prostate cancer

Fludrocortisone

Filters

45280 Abstracts